China Orders Additional Stockpile Of Sinovac Biotech’s Bird Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
China's Sinovac Biotech has been asked to step up production of its Panflu vaccine against the epidemic strain of the H5N1 virus in case of a bird flu epidemic. The State FDA said the addition to the current stockpile was sparked by eight cases of bird flu since December, five of them fatal. A spokeswoman said the situation was serious and that her agency also had initiated a program to inspect as it is produced so there are no delays if an outbreak occurs. Sinovac received clearance for Panflu last April for vaccinating humans ages 18 to 60. (Click here for more